



Date: 04th May, 2021.

To,
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai - 400 001.

Dear Sir,

Ref : Script Id "BAJAJHCARE", Script Code "539872".
Sub : Business Updates- Launch of Antiviral Favipiravir Tablets (brand name "Favijaj"),
for the Treatment of Mild to Moderate COVID-19

In terms of regulation 30 of SEBI (LODR) Regulations, 2015, please find attached herewith business updates - Launch of Antiviral Favipiravir Tablets (brand name "Favijaj"), for the Treatment of Mild to Moderate COVID-19.

Kindly take the same on record.

Thanking you,

For and on behalf of Board of Directors of
Bajaj Healthcare Limited

A handwritten signature in black ink, appearing to read 'Aakash'.

Aakash Kesari
Company Secretary

BAJAJ HEALTHCARE LIMITED

Registered Office : 602-606, Bhoomi Velocity Infotech Park, Plot No. B-39, B-39/A, B-39 A/1, Road No. 23, Wagle Ind. Estate, Thane(West), Thane-400 604.

• Tel. : + 91 22 6617 7400 - 499 • Fax : + 91 22 66177458 • Website : www.bajajhealth.com

CIN No. : L99999MH1993PLC072892



CIN: L99999MH1993PLC072892

Registered Office: 602-606, Bhoomi Velocity Infotech Park, Plot No. B-39, B-39A, B-39 A/1, Rd No.23, Wagle Ind. Estate Thane West, Maharashtra – 400604.

BHL launched Antiviral Favipiravir Tablets (brand name “Favijaj”), for the Treatment of Mild to Moderate COVID-19

Thane, 4th May 2021: Bajaj Healthcare Limited (BHL) a leading manufacturer of APIs, Intermediates and Formulations, has announced the launch of “Favijaj” (Favipiravir) an antiviral drug used for treating patients suffering from influenza virus and has proved to be effective over COVID patients. BHL has received approval from India's drug regulator, to manufacture and market “Favijaj” the oral Favipiravir approved medication in India for the treatment of COVID-19 from 4th May 2021.

“FAVIJAJ” tablets comprising Favipiravir in different dosage forms is used for the treatment of mild to moderate Covid-19 disease. Favipiravir is an antiviral drug, which has shown potent in vitro activity against severe acute respiratory syndrome of coronavirus.

Commenting on the launch of “Favijaj” (Favipiravir), Mr. Anil Jain, Joint Managing Director, Bajaj Healthcare said *“We are pleased to add Favipiravir to our growing product portfolios. The second waves is more aggressive and bigger in number than the first. We hope the availability of an effective treatment such as Favijaj will considerably ease the pressure, and offer patients much needed and timely therapy option.”*

BHL has successfully developed the active pharmaceutical ingredient (API) and the formulation for Favipiravir through its own in-house R&D team. Most patients ailing from mild to moderate symptoms can benefit from the use of Favijaj. The drug will be available as a prescription-based medication, with recommended doses.

The drug controller of India's has granted permissions to supply the “Favijaj” (Favipiravir) in the domestic as well as in overseas market.

About Bajaj Healthcare Limited

Bajaj Healthcare Limited a leading manufacturer of APIs, Intermediates and Formulations established in the year 1993. It specializes in manufacturing of Amino Acids, Intermediates, API, formulations & Nutraceuticals. The company has state-of-art manufacturing facilities, of which 6 units are dedicated to APIs, 2 units to Intermediates and 1 unit for formulation. These facilities are designed to meet the requirements of both advanced as well as emerging market opportunities. BHL has a strong presence globally in countries like Europe, USA, Australia, Africa, Middle East and South America.

For further information on the Company, please visit www.bajajhealth.com

Rupesh Nikam (CFO)

Bajaj Healthcare Limited

Contact: +91 22 6617 7400

Email: investors@bajajhealth.com

Krunal Shah/ Vinayak Shirodkar

Captive IR Strategic Advisors Pvt. Ltd.

Contact: +91 22 4347 2247

Email: krunal@cap-ir.com / Vinayak@cap-ir.com

Disclaimer:

CERTAIN STATEMENTS IN THIS DOCUMENT MAY BE FORWARD LOOKING STATEMENTS. SUCH FORWARD-LOOKING STATEMENTS ARE SUBJECT TO CERTAIN RISKS AND UNCERTAINTIES LIKE GOVERNMENT ACTIONS, LOCAL POLITICAL OR ECONOMIC DEVELOPMENTS, TECHNOLOGICAL RISKS, AND MANY OTHER FACTORS THAT COULD CAUSE OUR ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE CONTEMPLATED BY THE RELEVANT FORWARD-LOOKING STATEMENTS. BAJAJ HEALTHCARE LTD WILL NOT BE IN ANY WAY RESPONSIBLE FOR ANY ACTION TAKEN BASED ON SUCH STATEMENTS AND UNDERTAKES NO OBLIGATION TO PUBLICLY UPDATE THESE FORWARD-LOOKING STATEMENTS TO REFLECT SUBSEQUENT EVENTS OR CIRCUMSTANCE